Trials / Conditions / Mantle Cell Lymphoma Refractory
Mantle Cell Lymphoma Refractory
5 registered clinical trials studyying Mantle Cell Lymphoma Refractory — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Expo NCT05833763 | Australasian Leukaemia and Lymphoma Group | Phase 2 |
| Active Not Recruiting | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell NCT05864742 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Terminated | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL NCT05360238 | Mustang Bio | Phase 1 / Phase 2 |
| Terminated | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product NCT05645744 | Mustang Bio | — |
| Completed | Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patie NCT01389427 | The Lymphoma Academic Research Organisation | Phase 1 / Phase 2 |